Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
New approaches to influenza chemotherapy. Neuraminidase inhibitors
D. P. Calfee, F. G. Hayden
Research output
:
Contribution to journal
›
Review article
›
peer-review
133
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'New approaches to influenza chemotherapy. Neuraminidase inhibitors'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Chemotherapy
100%
Influenza
100%
Neuraminidase Inhibitors
100%
Zanamivir
100%
Influenza-like Illness
66%
Influenza B
66%
Anti-influenza
66%
Adverse Effects
33%
Clinical Trials
33%
Drug Effects
33%
Case Fatality Rate
33%
Clinical High Risk
33%
Influenza A
33%
Surface Glycoprotein
33%
Tolerability
33%
Armamentarium
33%
Aqueous Solution
33%
Human Influenza
33%
Antiviral Agents
33%
Inhibitory Activity
33%
Intranasal
33%
Local Concentration
33%
Ethyl Esters
33%
Rapid Development
33%
Protective Efficacy
33%
Underutilization
33%
Parent Compounds
33%
Respiratory Tract
33%
Influenza Neuraminidase
33%
Antiviral Resistance
33%
Clinical Resistance
33%
Topical Administration
33%
Antigenic Variation
33%
Amantadine
33%
Uniform Distribution
33%
Immunization Programs
33%
General Mortality
33%
Mortality in Elderly
33%
Rimantadine
33%
Administration by Inhalation
33%
Dry Powder Aerosol
33%
Ester Prodrug
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Sialidase Inhibitor
100%
Relenza
100%
Influenza
50%
Influenza B
50%
Oseltamivir
50%
4 Acetamido 5 Amino 3 (1 Ethylpropoxy) 1 Cyclohexene 1 Carboxylic Acid
50%
Adverse Event
25%
Disease
25%
Clinical Trial
25%
Infection
25%
Tolerability
25%
Antivirus Agent
25%
Case Fatality Rate
25%
Glycoprotein
25%
Prodrug
25%
Influenza A
25%
Seasonal Influenza
25%
Sialidase
25%
Amantadine
25%
Respiratory Tract
25%
Virus Resistance
25%
Rimantadine
25%